Regional citrate anticoagulation for continuous renal replacement therapy.

Area of Science:

• Nephrology
• Critical Care Medicine
• Pharmacology

Background:

• Effective anticoagulation is crucial for continuous renal replacement therapy (CRRT) circuit patency.
• Systemic heparin anticoagulation (SHA) and regional citrate anticoagulation (RCA) are the primary methods used.
• Understanding the nuances of RCA is essential for optimizing CRRT delivery.

Purpose of the Study:

• To review the fundamental principles and rationale behind regional citrate anticoagulation (RCA).
• To summarize existing data comparing the safety and efficacy of RCA versus SHA in CRRT.
• To provide evidence-based recommendations for anticoagulation strategies in CRRT.

Main Methods:

• Literature review of studies comparing SHA and RCA in CRRT.
• Analysis of data regarding filter lifetime, bleeding complications, and patient outcomes.
• Evaluation of RCA safety in diverse patient populations, including those with liver dysfunction and organ failure.

Main Results:

• RCA prolongs extracorporeal circuit filter lifespan significantly.
• RCA reduces the incidence of bleeding complications compared to SHA.
• RCA demonstrates excellent control over uremia and acid-base balance.
• RCA is generally safe in patients with impaired liver function, but requires caution in severe multiorgan failure with hyperlactatemia.

Conclusions:

• Regional citrate anticoagulation (RCA) is a safe and effective method for anticoagulating the CRRT circuit.
• RCA surpasses SHA in anticoagulation efficacy and safety profile.
• RCA is the preferred anticoagulation strategy for CRRT in the majority of intensive care unit patients.